<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251809</url>
  </required_header>
  <id_info>
    <org_study_id>MC-PEGASP.1/adults</org_study_id>
    <nct_id>NCT01251809</nct_id>
  </id_info>
  <brief_title>Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia</brief_title>
  <official_title>A Randomized, Multi-centre, Parallel-group, Open Label, Oncaspar® Controlled Dose Ranging Trial of Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>medac GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an assessment of efficacy and safety of three different doses of pegylated
      recombinant asparaginase (PEG-rASNase) in comparison to Oncaspar® during treatment of adults
      with de novo acute lymphoblastic leukaemia (ALL). This study will provide first data for
      determining specific asparaginase doses to yield various durations of L-asparagine (ASN)
      depletion which are required within different treatment phases of ALL therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the rate of patients with asparagine depletion 3 weeks after infusion of PEG-rASNase or Oncaspar® in the induction phase.</measure>
    <time_frame>3 weeks</time_frame>
    <description>To compare the rate of patients with asparagine depletion 3 weeks after infusion of PEG-rASNase or Oncaspar® in the induction phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing of treatment arms</measure>
    <time_frame>62 days</time_frame>
    <description>-the rate of patients with asparagine depletion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing of treatment arms</measure>
    <time_frame>62 days</time_frame>
    <description>the rate of patients with L-asparaginase (ASNase) activity levels in serum &gt; 100 U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing of treatment arms</measure>
    <time_frame>62 days</time_frame>
    <description>the duration of ASNase activity levels in serum &gt; 100 U/L and its variability pharmacokinetic parameters Cmax, t½, CLtotal, Kel, AUC0-t and AUC0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing of treatment arms</measure>
    <time_frame>62 days</time_frame>
    <description>the time profiles of ASNase activity and amino acid levels Asparagine (ASN), Aspartic acid (ASP), Glutamine (GLN) and Glutamic acid (GLU) in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing of treatment arms</measure>
    <time_frame>62 days</time_frame>
    <description>the incidence of increased bilirubin grade III/IV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing of treatment arms</measure>
    <time_frame>62 days</time_frame>
    <description>the incidence of all other adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Acute Lymphoblastic Leukaemia</condition>
  <arm_group>
    <arm_group_label>PEG-rASNase 500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 U/m2 BSA at day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-rASNase 1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 U/m2 BSA at day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-rASNase 1500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1500 U/m2 at day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oncaspar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2000 U/m2 at day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oncaspar</intervention_name>
    <description>2000 U/m2 BSA, single infusion</description>
    <arm_group_label>Oncaspar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rASNase</intervention_name>
    <description>500, 1000 or 1500 U/m2 BSA single infusion</description>
    <arm_group_label>PEG-rASNase 500</arm_group_label>
    <arm_group_label>PEG-rASNase 1000</arm_group_label>
    <arm_group_label>PEG-rASNase 1500</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated acute lymphoblastic leukaemia (pro-B, common, pre-B, early T,
             thymic T, mature T)

          -  Age 18 years - 55 years

          -  Treatment according to German Multicenter Trials for adult Acute Lymphoblastic
             Leukaemia (GMALL) 07/2003 protocol or subsequent GMALL protocols for patients with de
             novo ALL

          -  Written informed consent

          -  Women of child-bearing potential or partner of men with child-bearing potential must
             use a highly effective method of contraception

          -  Negative pregnancy test for women of child-bearing potential

        Exclusion Criteria:

          -  Patients with Philadelphia chromosome (BCR-ABL) positive ALL

          -  Severe comorbidity or leukaemia-associated complications

          -  Known hypersensitivity to asparaginase

          -  History of severe pancreatitis

          -  History of thrombosis or pulmonary embolism

          -  Pre-existing clinically relevant coagulopathy

          -  Liver dysfunction (e.g. acute or current hepatitis, alcohol or drug abuse) or history
             of clinically relevant liver disease

          -  Bilirubin &gt; 1.5 x Upper Limit Norm (ULN)

          -  Other current malignancies

          -  Severe psychiatric illness or other circumstances which may compromise the cooperation
             of the patient or the ability to give informed consent

          -  Body mass index &gt; 30 kg/m²

          -  Known pregnancy, breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Gökbuget, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Frankfurt, Medizinische Klinik II, Theodor-Stern-Kai 7, 60590, Frankfurt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin Hämatologie, Onkologie, Transfusionsmedizin Medizinische Klinik III</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité University Hospital Campus Virchow</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Bonn, Medizinische Klinik &amp; Poliklinik III</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig Medizinische Klinik III</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Carl Gustav Carus der Technischen Universität</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johannes-Hospital</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Erlangen-Nürnberg Med. Klinik V/Hämatologie</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen Westdeutsches Tumorzentrum</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt Medizinische Klinik II</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen Hämatologie / Onkologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Krankenhaus Hagen gGmbH Klinik für Hämatologie und Onkologie</name>
      <address>
        <city>Hagen</city>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg Hämatologie &amp; Stammzelltransplantation</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona II. Medizinische Abteilung</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Medizinische Klinik Hämatologie/Onkologie</name>
      <address>
        <city>Hamm</city>
        <zip>59063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig José-Carreras-Haus Abt. Hämatologie / Onkologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz III. Medizinische Klinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwabing, Klinik für Hämatologie, Onkologie, Immunologie, Palliativmedizin, Infektiologie &amp; Tropenmedizin</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar der TU München III. Medizinische Klinik</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg, 5. Medizinische Klinik</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg Innere Medizin II</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann, Zentrum für Hämatologie, Onkologie und Strahlenheilkunde</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Rostock, Zentrum für Innere Medizin, Klinik III</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Bosch-Krankenhaus Abt. Hämatologie / Onkologie</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Ulm Klinik für Innere Medizin III Zentrum für Innere Medizin</name>
      <address>
        <city>Ulm</city>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <last_update_submitted>May 17, 2013</last_update_submitted>
  <last_update_submitted_qc>May 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asparaginase</keyword>
  <keyword>ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

